At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
BNTC Benitec Biopharma
Market Closed 12-20 16:00:00 EST
11.41
-0.76
-6.24%
盘后11.41
+0.000.00%
18:56 EST
High12.40
Low11.41
Vol562.05K
Open12.02
D1 Closing12.17
Amplitude8.13%
Mkt Cap264.90M
Tradable Cap121.88M
Total Shares23.22M
T/O6.48M
T/O Rate5.26%
Tradable Shares10.68M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Hedge funds investors own a significant stake of 38% in Benitec Biopharma Inc. (NASDAQ:BNTC)
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. Benitec Biopharma Inc. was incorporated in 1995 and is headquartered in Hayward, California.